Clinical Trial: Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT06835400) titled 'Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer' on Feb. 14.

Brief Summary: The current study is being conducted to find an optimal Oral Paclitaxel + Encequidar dose and regimen based on prior experience with oral paclitaxel (stage 1) and to compare that dose to an accepted dose and regimen of intravenous (IV) paclitaxel in subjects with metastatic breast cancer (stage 2).

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: Metastatic Breast Cancer

Intervention: DRUG: Paclitaxel Capsule

Paclitaxel Capsule

DRUG: IV Paclitaxel

IV Paclitaxel

DRUG: Encequidar...